| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
As a ginsenoside, Rh7 is believed to target multiple cellular pathways involved in cancer cell proliferation, apoptosis, and immune regulation. The molecular targets of ginsenosides generally include NF-kappaB, MAPK, PI3K/Akt, and AMPK signaling pathways. Ginsenosides also modulate the expression of various genes involved in cell cycle regulation, such as p53, p21, and cyclins. Specific high-affinity receptor targets for Rh7 have not been fully characterized.
|
|---|---|
| ln Vitro |
Ginsenoside Rh7 has been reported to exhibit cytotoxicity against human leukemia cell lines. In vitro studies have shown that it can inhibit cell viability and induce apoptosis in cancer cells. Detailed IC50 values for Rh7 against specific cancer cell lines are not widely reported in standard literature, but related ginsenosides demonstrate potent anti-cancer activities. The compound is soluble in organic solvents such as DMSO, chloroform, and ethyl acetate, and is stable as a powder at -20degC.
|
| ln Vivo |
The in vivo activity of Ginsenoside Rh7 has not been extensively reported. However, as a minor ginsenoside from Panax ginseng, it is expected to contribute to the overall pharmacological effects of ginseng extracts, which include anti-cancer, anti-inflammatory, and immunomodulatory activities. Related ginsenosides have demonstrated efficacy in mouse models of tumor xenografts, inflammation, and oxidative stress. Further detailed in vivo studies are needed to characterize the specific efficacy of Rh7.
|
| Enzyme Assay |
A standard biochemical assay for ginsenosides is an NF-kappaB activity assay using a reporter gene construct. HEK293 cells are transfected with an NF-kappaB luciferase reporter plasmid and a control Renilla plasmid. Cells are treated with varying concentrations of Ginsenoside Rh7 for 24-48 hours, and then lysed. Luciferase activity is measured using a dual-luciferase assay system. A decrease in luminescence compared to vehicle control indicates inhibition of the NF-kappaB signaling pathway.
|
| Cell Assay |
An in vitro cellular assay for Ginsenoside Rh7 is a cytotoxicity assay using human cancer cell lines such as K562 (chronic myeloid leukemia) and HL60 (acute promyelocytic leukemia). Cells are seeded in 96-well plates and treated with varying concentrations of Rh7 (e.g., 0-100 microM) for 48-72 hours. Cell viability is measured using an MTT or CCK-8 assay. The half-maximal inhibitory concentration (IC50) is calculated from the dose-response curve. Apoptosis can be confirmed by Annexin V/PI staining and flow cytometry.
|
| Animal Protocol |
To study the in vivo efficacy of Ginsenoside Rh7, a mouse xenograft model is appropriate. Immunodeficient mice are subcutaneously implanted with human cancer cells (e.g., K562 or HL60) (1-5 × 10⁶ cells/mouse). When tumors reach approximately 50-100 mm3, mice are randomized into vehicle control and treatment groups. Rh7 is administered at doses of 10-50 mg/kg (i.p. or oral gavage) daily or every other day for 2-4 weeks. Tumor volume (length×width2/2) and body weight are measured every 3-4 days. Endpoints include tumor growth inhibition (TGI), terminal tumor weight, and histopathological analysis (TUNEL, Ki-67 staining).
|
| ADME/Pharmacokinetics |
Ginsenoside Rh7 has a molecular weight of 636.86 and is a lipophilic triterpene saponin. For in vivo administration, it is formulated in vehicles such as 0.5% CMC-Na (carboxymethylcellulose sodium) or a mixture of DMSO, PEG300, Tween 80, and saline. Pharmacokinetic parameters for Rh7 are not widely reported. As a ginsenoside, it is expected to have poor oral bioavailability due to its large molecular weight and poor membrane permeability; however, it may be absorbed to some extent via intestinal transporters. The elimination half-life in rats is typically short (1-4 hours) for ginsenosides when administered intravenously.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for Ginsenoside Rh7 is not available. As a natural product from Panax ginseng, which has a long history of safe use in traditional medicine, ginsenosides are generally considered to have a low toxicity profile. High doses of some ginsenosides can cause mild adverse effects such as insomnia, gastrointestinal upset, or changes in blood pressure. The compound should be handled as a potential bioactive natural product with standard laboratory safety precautions.
|
| References | |
| Additional Infomation |
Ginsenoside Rh7 is a triterpenoid saponin. It has been reported that ginseng contains ginsenoside Rh7, and relevant data is available for reference.
While Ginsenoside Rh7 itself has limited published data, it is one of the minor saponins isolated from the leaves of Panax ginseng, along with other new saponins like ginsenosides Rh5, Rh6, Rh8, Rh9, and Rh10. The identification of these minor ginsenosides has contributed to a broader understanding of the chemical diversity and pharmacological potential of ginseng. Ginseng has been used for centuries in traditional medicine for its adaptogenic, anti-stress, and anti-aging properties. Ginsenoside Rh7 is strictly a research-grade natural product, not a pharmaceutical drug, and is not approved for any clinical indications. |
| Molecular Formula |
C36H60O9
|
|---|---|
| Molecular Weight |
636.86
|
| Exact Mass |
636.423
|
| CAS # |
343780-68-7
|
| PubChem CID |
101096472
|
| Appearance |
White to off-white solid
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
764.1±60.0 °C at 760 mmHg
|
| Flash Point |
415.9±32.9 °C
|
| Vapour Pressure |
0.0±5.9 mmHg at 25°C
|
| Index of Refraction |
1.590
|
| LogP |
3.22
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
45
|
| Complexity |
1170
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
O[C@@H]1C[C@@H]2[C@@]3(C)CC[C@@H](C(C)(C)C3=C[C@@H]([C@@]2(C)[C@]2(C)CC[C@H]([C@](C)(CC/C=C(\C)/C)O[C@H]3[C@@H]([C@H]([C@@H]([C@@H](CO)O3)O)O)O)[C@H]21)O)O
|
| InChi Key |
ARPGURKWJGBPTN-SAEPZWPDSA-N
|
| InChi Code |
InChI=1S/C36H60O9/c1-19(2)10-9-13-35(7,45-31-30(43)29(42)28(41)22(18-37)44-31)20-11-15-34(6)27(20)21(38)16-24-33(5)14-12-25(39)32(3,4)23(33)17-26(40)36(24,34)8/h10,17,20-22,24-31,37-43H,9,11-16,18H2,1-8H3/t20-,21+,22+,24+,25-,26-,27-,28+,29-,30+,31-,33-,34+,35-,36-/m0/s1
|
| Chemical Name |
(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[(2S)-6-methyl-2-[(3S,7S,8R,9R,10R,12R,13R,14R,17S)-3,7,12-trihydroxy-4,4,8,10,14-pentamethyl-2,3,7,9,11,12,13,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]hept-5-en-2-yl]oxyoxane-3,4,5-triol
|
| Synonyms |
Ginsenoside Rh7
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5702 mL | 7.8510 mL | 15.7020 mL | |
| 5 mM | 0.3140 mL | 1.5702 mL | 3.1404 mL | |
| 10 mM | 0.1570 mL | 0.7851 mL | 1.5702 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
